Strategies and challenges for the next generation of antibody–drug conjugates

Volume: 16, Issue: 5, Pages: 315 - 337
Published: Mar 17, 2017
Abstract
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that are evaluating more than 60 further ADC candidates. The limited success of first-generation ADCs (developed in the early 2000s) informed strategies to bring second-generation ADCs to...
Paper Details
Title
Strategies and challenges for the next generation of antibody–drug conjugates
Published Date
Mar 17, 2017
Volume
16
Issue
5
Pages
315 - 337
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.